Loblaw, the popular grocery retailer, announced an increase in profits for the second quarter, attributing the growth to the success of its discount chains, No Frills and Maxi. The company also highlighted strong sales performance in its pharmacy division, particularly driven by the popularity of generic GLP-1 weight loss medications.
Based in Brampton, Ontario, Loblaw disclosed its financial results for the quarter ending June 20, with revenue exceeding $15.3 billion, marking a four percent increase from the previous quarter. Profit available to common shareholders rose by five percent to $751 million.
The company reported a 1.6 percent rise in same-store sales for its core retail food business and a notable 4.6 percent increase in the drug retail unit, driven by a significant 7.5 percent growth in pharmacy and health-care services.
During a conference call with analysts, Loblaw’s CFO, Richard Dufresne, highlighted the positive impact of the generic GLP-1 drugs on the pharmacy performance. He emphasized that lower generic drug prices were being offset by higher volumes, leading to expectations of increased revenue, gross profit dollars, and gross margin rates.
The company noted a substantial 40 percent year-to-date increase in GLP-1 drug sales, demonstrating a growing trend that began in the previous quarter. CEO Per Bank mentioned that cost-conscious customers are increasingly opting for frozen vegetables over fresh produce due to inflationary pressures, with frozen vegetable sales experiencing over five percentage points growth in the No Frills and Maxi stores.
Loblaw executives expressed confidence in their ability to cater to value-seeking customers amidst food price inflation, with their hard discount stores performing well compared to conventional retailers. The company’s internal food inflation metric remains lower than the national grocery CPI, indicating a strong market position.
In other economic news, Canada’s inflation rate reduced to 2.8 percent in June, with grocery price increases easing to 3.9 percent from the previous month’s 4.3 percent. Loblaw’s shares traded steadily on Thursday, reflecting a year-to-date gain of approximately six percent.